Health Discovery (HDVY) 10-Q 13 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 13, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	333-62216
Entity Registrant Name	HEALTH DISCOVERY CORPORATION
Entity Central Index Key	0001141788
Entity Tax Identification Number	74-3002154
Entity Incorporation, State or Country Code	GA
Entity Address, Address Line One	2002 Summit Blvd NE
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30319
City Area Code	404
Local Phone Number	566-4865
Title of 12(b) Security	Common stock, no par value
Trading Symbol	Hdvy
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		404,378,270

BALANCE SHEETS (Unaudited)

BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 485	$ 917
Prepaid expenses	15	15
Total current assets	500	932
Patents, net of accumulated amortization of $3,986
Total assets	500	932
Current liabilities:
Accounts payable	366	128
Dividends payable	207	207
Accrued interest	18	10
Convertible debt	212	212
Total current liabilities	803	557
Total liabilities	803	557
Shareholders’ (deficit) equity:
Series D convertible preferred stock, no par value, 90,000,000 shares authorized: 20,991,891 issued and outstanding at June 30, 2021 and December 31, 2020	217	217
Common stock, no par value, 900,000,000 shares authorized: 404,378,270 and 404,044,937 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	31,675	30,297
Accumulated deficit	(32,195)	(30,139)
Total shareholders’ (deficit) equity	(303)	375
Total liabilities and shareholders’ (deficit) equity	$ 500	$ 932

BALANCE SHEETS (Unaudited) (Par

BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accumulated Amortization	$ 3,986	$ 3,986
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	90,000,000	90,000,000
Preferred stock, shares issued	20,991,891	20,991,891
Preferred stock, shares outstanding	20,991,891	20,991,891
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	404,378,270	404,044,937
Common stock, shares outstanding	404,378,270	404,044,937

STATEMENTS OF OPERATIONS (Unaud

STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Licensing and development revenue	$ 0	$ 1	$ 0	$ 1
Operating expenses:
Professional and consulting fees	14	167	78	192
Legal fees	116	33	301	185
Compensation	114	130	216	236
Other general and administrative expenses	1,426	444	1,453	485
Total operating expenses	1,670	774	2,048	1,098
Loss from operations	(1,670)	(773)	(2,048)	(1,097)
Other (expense) income, net:
Interest income	0	0	0	1
Interest expense	(4)	(1)	(8)	(1)
Change in fair value of common stock warrants liability	0	2,186	0	992
Other expense, net	(4)	2,185	(8)	992
Net (loss) income	$ (1,674)	$ 1,412	$ (2,056)	$ (105)
Net (loss) income per share:
Basic	$ (0.004)	$ 0.004	$ (0.005)
Diluted	$ (0.004)	$ 0.003	$ (0.005)
Basic	404,348,966	393,553,617	404,197,791	391,113,557
Diluted	404,348,966	464,320,598	404,197,791	391,113,557

STATEMENTS OF SHAREHOLDERS' EQU

STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Series D Convertible Preferred Stock [Member]	Common Stock [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019		$ 28,910	$ (29,380)	$ (470)
Beginning balance, shares at Dec. 31, 2019		388,646,386
Promissory note and accrued interest converted to Series D convertible preferred stock	$ 217			217
Promissory note and accrued interest converted to Series D convertible preferred stock, shares	20,991,891
Issuance of common stock in settlement of accrued wages		$ 213		213
Issuance of common stock in settlement of accrued wages, shares		15,398,551
Reclassification of common stock warrants liability		$ 906		906
Stock-based compensation expense		268		268
Net loss			(105)	(105)
Ending balance, value at Jun. 30, 2020	$ 217	$ 30,297	(29,485)	1,029
Ending balance, shares at Jun. 30, 2020	20,991,891	404,044,937
Beginning balance, value at Mar. 31, 2020	$ 217	$ 28,910	(30,897)	(1,770)
Beginning balance, shares at Mar. 31, 2020	20,991,891	388,646,386
Issuance of common stock in settlement of accrued wages		$ 213		213
Issuance of common stock in settlement of accrued wages, shares		15,398,551
Reclassification of common stock warrants liability		$ 906		906
Stock-based compensation expense		268		268
Net loss			1,412	1,412
Ending balance, value at Jun. 30, 2020	$ 217	$ 30,297	(29,485)	1,029
Ending balance, shares at Jun. 30, 2020	20,991,891	404,044,937
Beginning balance, value at Dec. 31, 2020	$ 217	$ 30,297	(30,139)	375
Beginning balance, shares at Dec. 31, 2020	20,991,891	404,044,937
Reclassification of common stock warrants liability				0
Issuance of common stock pursuant to exercise of warrant		$ 10		10
Issuance of common stock pursuant to exercise of warrant, shares		333,333
Stock-based compensation expense		$ 1,368		1,368
Net loss			(2,056)	(2,056)
Ending balance, value at Jun. 30, 2021	$ 217	$ 31,675	(32,195)	(303)
Ending balance, shares at Jun. 30, 2021	20,991,891	404,378,270
Beginning balance, value at Mar. 31, 2021	$ 217	$ 30,297	(30,521)	(7)
Beginning balance, shares at Mar. 31, 2021	20,991,891	404,044,937
Issuance of common stock pursuant to exercise of warrant		$ 10		10
Issuance of common stock pursuant to exercise of warrant, shares		333,333
Stock-based compensation expense		$ 1,368		1,368
Net loss			(1,674)	(1,674)
Ending balance, value at Jun. 30, 2021	$ 217	$ 31,675	$ (32,195)	$ (303)
Ending balance, shares at Jun. 30, 2021	20,991,891	404,378,270

STATEMENTS OF CASH FLOWS (Unaud

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (2,056)	$ (105)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,368	268
Change in fair value of common stock warrants liability	0	(992)
Changes in operating assets and liabilities:
Prepaid expenses	0	2
Accounts payable	238	207
Accrued wages	0	(15)
Accrued interest	8	1
Net cash used in operating activities	(442)	(634)
Cash flows from financing activities
Proceeds from warrant exercise	10	0
Net cash provided by financing activities	10	0
Net decrease in cash	(432)	(634)
Cash, beginning of period	917	2,296
Cash, end of period	485	1,662
Non-cash Financing and Investing Activities
Conversion of debt to Series D convertible preferred stock	0	217
Conversion of accrued wages to common stock	0	213
Conversion of accrued wages to note payable	0	212
Reclassification of common stock warrants liability	$ 0	$ 906

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION	Note 1 - BASIS OF PRESENTATION Health Discovery Corporation (the “Company”) is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery. The terms artificial intelligence and machine learning are sometimes used to describe pattern recognition tools. Our mission is to use our patents and clinical partnerships principally to identify patterns that can advance the science of medicine, as well as to advance the effective use of our technology in other diverse business disciplines, including the high-tech, financial, and healthcare technology markets. Our historical foundation lies in the molecular diagnostics field where we have made a number of discoveries that may play a role in developing more personalized approaches to the diagnosis and treatment of certain diseases. However, our Support Vector Machines (“SVM”) assets in particular have broad applicability in many other fields. Intelligently applied, our pattern recognition technology can be a portal between enormous amounts of otherwise undecipherable data and truly meaningful discovery. Our principal asset is our intellectual property, which includes advanced mathematical algorithms called SVM, as well as biomarkers that we discovered by applying our SVM techniques to complex genetic and proteomic data. Biomarkers are biological indicators or genetic expression signatures of certain disease states. Our intellectual property is protected by 21 patents that have been issued or are currently pending around the world. Our business model has evolved over time to respond to business trends that intersect with our technological expertise and our capacity to professionally manage these opportunities. In the beginning, we sought only to use our SVMs internally in order to discover and license our biomarker signatures to various diagnostic and pharmaceutical companies. Today, our commercialization efforts include: utilization of our discoveries and knowledge to help develop diagnostic and prognostic predictive tests; licensing of the SVM technologies directly to diagnostic companies; and, the potential formation of new ventures with domain experts in other fields where our pattern recognition technology holds commercial promise. The accompanying interim financial statements included in this report are unaudited but reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial position and results of operations for the interim periods presented for the Company. All such adjustments are of a normal recurring nature. The accounting principles followed by the Company and the methods of applying these principles conform with accounting principles generally accepted in the United States of America (“GAAP”). Interim results are not necessarily indicative of the results of a full year’s operations and should be read in conjunction with the financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2020. Liquidity and Going Concern The Company has prepared its financial statements on a “going concern” basis, which presumes that it will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company’s ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing, successfully bringing the Company’s technologies to the market and successfully pursuing infringement opportunities. The outcome of these matters cannot be predicted at this time. The Company’s financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should the Company be unable to continue in business. If the going concern assumption was not appropriate for the Company’s financial statements then adjustments would be necessary in the carrying values of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments may be material. At June 30, 2021, the Company had approximately $ 485,000 The Company’s plan to have sufficient cash involves licensing the Company patents, pursuing infringement opportunities and obtaining additional equity or debt financing. While the Company believes these efforts may increase the value of the Company, there is no guarantee that the Company will be successful in these efforts. We estimate cash will be depleted by the first quarter of 2022 unless we are able to increase revenues or raise additional capital. Estimates and assumptions In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts in the financial statements. Actual results could differ significantly from those estimates due to risks and uncertainties, including uncertainty in the current economic environment due to the outbreak of a novel strain of COVID-19. Segments In making decisions regarding resource allocation and assessing performance, our chief executive officer and president view our operations and manages our business as one operating segment.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	Note 2 – SIGNIFICANT ACCOUNTING POLICIES Patents Initial costs paid to purchase patents are capitalized and amortized using the straight-line method over the remaining life of the patent, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the three and six months ended June 30, 2021, and 2020 there was no no Common Stock Warrants Liability The Company has, from time to time beginning in 2014, issued convertible preferred stock, preferred stock warrants, common stock, common stock warrants, and fully vested options to purchase shares of common stock in excess of its available shares of underlying stock to be issued. In the event the number of shares or warrants of common stock granted exceeds the number of shares available if the holders exercised all of the previously issued outstanding options and warrants, the Company accounts for this excess as a derivative which is recorded as a common stock warrants liability, which is adjusted to fair value at the end of each reporting period. If and when the Company authorizes sufficient shares of common stock and preferred stock, the common stock warrants liability is reclassified to equity at the fair value of the liability at the date of reclassification. The Company accounts for the See further discussion in Note 6 –Shareholders’ Equity (Deficit) and Note 7– Common Stock Warrants Liability. Stock-based Compensation Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period using the straight-line method. Valuation and Amortization Method Expected Term Expected Volatility – Risk-Free Interest Rate Cash Cash includes cash deposited with financial institutions. Periodically, we maintain deposits in financial institutions in excess of government-insured limits. We believe we are not exposed to significant credit risk and to date, we have not realized any losses on these deposits.

NET (LOSS) INCOME PER SHARE

NET (LOSS) INCOME PER SHARE	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
NET (LOSS) INCOME PER SHARE	Note 3 – NET (LOSS) INCOME PER SHARE Basic earnings per share (“EPS”) is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding stock options, convertible promissory notes payable, convertible preferred stock, and warrants. The computation of basic and diluted earnings per share was as follows: Computation of earnings per share Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net (loss) income, in thousands $ (1,674 ) $ 1,412 $ (2,056 ) $ (105 ) Weighted average shares outstanding – basic 404,348,966 393,553,617 404,197,791 391,113,557 Effect of dilutive securities: Shares issuable on conversion of options and warrants – 34,376,539 – – Shares issuable on conversion of convertible debt – 15,398,551 – – Shares issuable on conversion of Series D convertible preferred stock – 20,991,891 – – Weighted average shares outstanding – diluted 404,348,966 464,320,598 404,197,791 391,113,557 (Loss) Earnings per share: Basic $ (0.004 ) $ 0.004 $ (0.005 ) $ – Diluted $ (0.004 ) $ 0.003 $ (0.005 ) $ – Anti-dilutive shares excluded: Shares issuable on conversion of options and warrants 94,587,577 – 82,597,604 37,732,532 Shares issuable on conversion of convertible debt 16,728,311 – 16,728,311 15,398,551 Shares issuable on conversion of Series D convertible preferred stock 20,991,891 – 20,991,891 20,991,891 The dilutive effect of 6,108,502 105,869,976 9,951,284 22,843,491

STOCK-BASED COMPENSATION AND OT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS	Note 4 – STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS As of June 30, 2021, there was no 7.3 In connection with their election to the Company’s Board of Directors at the Shareholder Meeting and in recognition of their continuing contributions to the Company without cash compensation, on June 29, 2021, the Company granted to Mr. William Fromholzer, Ms. Colleen Hutchinson, Mr. Ed Morrison, and Mr. James Murphy each an option to purchase 3,000,000 5,000,000 3,000,000 0.065 June 29, 2031 0.0595 0 0.37 5 154 1,368,500 Stock-based compensation expense recorded in the financial statements was approximately $ 1.4 268,000 The following schedule summarizes common stock option information as of December 31, 2020 and June 30, 2021. Schedule of stock option activity Shares Weighted-Average Outstanding, December 31, 2020 63,875,000 $ 0.025 Granted 23,000,000 $ 0.065 Exercised – $ – Forfeited – $ – Outstanding and exercisable, June 30, 2021 86,875,000 $ 0.036 The following schedule summarizes common stock warrant information as of December 31, 2020 and June 30, 2021. Schedule of common stock warrant activity Shares Weighted-Average Outstanding, December 31, 2020 115,983,781 $ 0.025 Granted – $ – Exercised (333,333 ) $ (0.03 ) Forfeited – $ – Outstanding, June 30, 2021 115,650,448 $ 0.025 At June 30, 2021 and December 31, 2020, the Company had 86,875,000 63,875,000 $0.003 to $0.070 115,650,448 115,983,781 $0.005 to $0.075

PATENTS

PATENTS	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS	Note 5 – PATENTS The Company’s principal asset is its intellectual property, which includes advanced mathematical algorithms called Support Vector Machines (“SVM”), as well as biomarkers that we discovered by applying its SVM techniques to complex genetic and proteomic data. Biomarkers are biological indicators or genetic expression signatures of certain disease states. The Company’s intellectual property is protected by 21 2022 to 2033 For the three and six months ended June 30, 2021, and 2020 there was no amortization charged to operations as the patents are fully amortized. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs.

SHAREHOLDERS_ EQUITY (DEFICIT)

SHAREHOLDERS’ EQUITY (DEFICIT)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
SHAREHOLDERS’ EQUITY (DEFICIT)	Note 6 – SHAREHOLDERS’ EQUITY (DEFICIT) Authorized capital At June 30, 2021 and December 31, 2020, the Company’s authorized capital consisted of 900,000,000 shares of common stock and 90,000,000 shares of preferred stock. Series B Preferred Stock The Company sold to individual investors a total of 19,402,675 shares of Series B preferred shares for $1,490,015, net of associated expenses, in 2009. The Series B preferred shares were converted into common stock of the Company in the fourth quarter of 2014, which was the fifth anniversary of the date of issuance as outlined in the original purchase agreement. There are currently no Series B preferred shares outstanding. Dividends were accrued for the Series B preferred stock in the amount of $373,346 as of December 31, 2014. The Company gave the Series B holders the choice of either (1) common stock for the amount of the dividend accrued based upon the price of $0.05 per share or (2) to defer payment of the dividend in cash until the Company is able to pay, at the sole discretion of the Company. During the first quarter of 2015, $166,709 in dividends were paid with the issuance of 3,334,179 shares of common stock. The remaining accrued dividend of $ 206,637 Series C Preferred Stock In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C preferred shares in private placement transactions. As of December 31, 2014, and 2015, the Company had issued a total of 6,640,000 and 30,000,000 preferred shares, respectively. The Series C preferred shares were fully subscribed in the third quarter 2015. The Company received total net proceeds of $900,000, of which $568,000 was received during the year ended December 31, 2015. The Series C preferred shares were accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants were to be issued only if the Company had not attained profitability by the end of the first quarter 2016. Because the Company did not attain profitability by the end of first quarter 2016, the contingency warrants were issued. The warrant holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days. The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days. The warrants were valued at $0.022 each using the Black Scholes Method. The Series C preferred stock were to be converted into common stock of the Company at the option of the holder, without the payment of additional consideration by the holder. The shares of Series C preferred stock must be converted into common stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. During the first quarter of 2019, the Series C preferred stock was converted to common stock. There are currently no Series C preferred shares outstanding. Series D Preferred Stock In February 2020, the Company effected the conversion of its $ 200,000 16,688 41,983,781 0.0103 July 31, 2029 The Company’s Series D preferred stock has the following rights and preferences: Dividend rights pari passu Voting rights Conversion rights Liquidation rights pari passu Common Stock On June 9, 2021, the Company issued 333,333 0.03 In June 2020, the Chairman of the Board and the Company entered into an agreed upon settlement whereby accrued wages of $ 212,500 15,398,551 0.0138 All of these issuances of equity securities were made in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended. At June 30, 2021 and December 31, 2020, the Company had 86,875,000 63,875,000 $0.003 to $0.070 115,650,448 115,983,781 $0.005 to $0.075

COMMON STOCK WARRANTS LIABILITY

COMMON STOCK WARRANTS LIABILITY	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
COMMON STOCK WARRANTS LIABILITY	Note 7 – COMMON STOCK WARRANTS LIABILITY The common stock warrants liability is recorded based upon the vested number of warrants or other equity-linked instruments outstanding which exceed the number of authorized shares available to meet the assumed exercise or conversion of such instruments at each reporting period. The common stock warrants liability is recorded based upon the number of warrants which exceed the number of common shares available to meet the exercised options and warrants using the Black-Scholes option-pricing model. During the three months ended June 30, 2020, the Company recorded other income of $2.2 million related to the change in common stock warrants liability. In the six months ended June 30, 2020, the Company recorded other income of $992,000 related to the reduction of the common stock warrants liability. At June 30, 2021 and December 31, 2020, the common stock warrants liability was zero as the Company reclassified the common stock warrants liability to equity, as our shareholders approved the necessary increase in authorized share capital at our annual shareholder meeting held in May 2020. The Company now has adequate authorized shares available to meet the assumed exercise or conversion of its issued options, warrants, convertible debt and convertible preferred stock. The following table presents a reconciliation of the Company’s common stock warrants liability for the six months ended June 30, 2020 (in thousands): Reconciliation of warrant liability Common Stock Warrants Liability Balance, December 31, 2019 $ 1,898 Change in fair value of common stock warrants liability (992 ) Reclassification of common stock warrants liability to equity (906 ) Balance, June 30, 2020 $ – The Company has determined that the common stock warrants liability is a Level 3 measurement within the fair value hierarchy.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
CONVERTIBLE DEBT	Note 8 – CONVERTIBLE DEBT In April 2019, the Company issued a convertible promissory note in the amount of $200,000 to Mr. George McGovern, the Chairman and Chief Executive Officer of the Company, and Mr. James Dengler, a Company shareholder (the “Note Holders”) for funds advanced to the Company. The promissory note was approved by the Company’s board of directors in 2018, for funds advanced to the Company from August 2018 through March 2019 and the promissory note was executed in April 2019 by the Company. This promissory note contained an 8% annual interest rate, and the Note Holders had the right to convert the principal and unpaid accrued interest of the promissory note (the “2019 Convertible Promissory Note”) into shares of the Company’s Series D convertible preferred stock at a conversion price based upon the price of the Company’s common stock on the date of advancement of the loan amount (the “Conversion Price”). Because the loan proceeds were advanced on multiple dates, the Conversion Price varies depending upon the price of the Company’s common stock on the date of advancement of the loan amount. The right of conversion (optional) was solely at the Note Holders’ discretion. On December 31, 2019, the Note Holders notified the Company of their election to convert the 2019 Convertible Promissory Note into shares of the Company’s Series D convertible preferred stock. As a result, the Note Holders received 20,991,891 In June 2020, $ 212,000 0.0138 8

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	Note 9 – FAIR VALUE MEASUREMENT The carrying values of our prepaid expenses and accounts payable approximate their recorded values due to the short-term nature of these instruments. The common stock warrants liability is recorded based on the number of warrants which exceed the number of common shares available to meet the exercised options and warrants using the Black-Scholes option pricing model. The Company has determined that the common stock warrants liability is a Level 3 measurement within the fair value hierarchy. See further discussion of the Common Stock Warrants Liability in Note 7 – Common Stock Warrants Liability. On January 1, 2021, the Company adopted the provisions of Accounting Standards Update (“ASU”) No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The new standard modifies the disclosure requirements on fair value measurements in Topic 820, “Fair Value Measurement.” Certain requirements were removed such as the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, certain requirements were modified and certain disclosures were added such as the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations and cash flows.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 10 – COMMITMENTS AND CONTINGENCIES Operating Leases The Company does not own any real property. The Company leases approximately 300 square feet of office space in Atlanta, Georgia, pursuant to a short-term lease as of January 2021. The Company currently pays base rent in the amount of $636 per month. Legal Proceedings Intel Matter As previously disclosed, the USPTO had declared an Interference between the Company’s Support Vector Machine – Recursive Feature Elimination (“SVM-RFE”) patent application and Intel Corporation’s (“Intel”) Patent No. 7,685,077, entitled “Recursive Feature Eliminating Method based on a Support Vector Machine”. On February 27, 2019, the USPTO ruled in favor of the Company on the SVM-RFE patent application. The Patent Trial and Appeal Board (“PTAB”) of the USPTO issued its decision, finding that HDC is entitled to claim exclusive ownership rights to the SVM-RFE technology as set forth in the SVM-RFE patent application that was filed to provoke the Interference. The decision ordered Intel Corporation’s Patent No. 7,685,077 to be cancelled. In September 2019, the USPTO issued U.S. Patent No. 10,402,685 (“SVM-RFE Patent”) for the Company’s patent application covering SVM-RFE. The Company is the sole owner of all patents related to SVM-RFE. As a result of the issuance of the SVM-RFE Patent, the Company now has the right to exclude others from developing, commercializing, or licensing this patented technology without the uncertainty of the Interference or concerns over the ownership of the SVM-RFE patents. Furthermore, the USPTO granted a Patent Term Adjustment (“PTA”) to the SVM-RFE Patent. The PTA is 1,785 days (almost 5 years), which is added to the normal 20-year-from-filing patent term. The USPTO granted this adjustment to offset delays that occurred within the USPTO during the examination process and interference proceedings. This means the SVM-RFE Patent term has been extended from August 7, 2020, to June 7, 2025. On July 23, 2020, the Company filed a patent infringement lawsuit (“Infringement Lawsuit”) against Intel pertaining to the Company’s SVM-RFE technology. The lawsuit was filed in the United States District Court for the Western District of Texas, Waco Division (the “Court”). Subsequently, on October 19, 2020, Intel filed a motion to dismiss with the Court. On November 23, 2020, the Company filed a response in opposition of Intel’s motion to dismiss. On December 21, 2020, the Court approved a scheduling order (“Scheduling Order”) for the Infringement Lawsuit. One of the items in the Scheduling Order was the Markman Markman Markman Markman Once briefing concluded on May 18, 2021, HDC and Intel submitted a Joint Claim Construction Statement to the Court. Within that Joint Claim Construction Statement, the parties identified several claim terms (i.e., key words) that were still in dispute. During the Markman Markman On February 27, 2021, Intel filed a Petition for Inter Partes Legal fees for this matter were $ 116,000 0 205,000 0 Quirk and Bear Matter On February 7, 2020, two shareholders of the Company, William F. Quirk, Jr. (“Quirk”) and Cindy Bear (“Bear”), filed a complaint and motion for a temporary restraining order and preliminary injunction in DeKalb County Superior Court. Among the items in the motion, Quirk and Bear requested to have a special meeting of the shareholders and Quirk and Bear alleged misconduct by the Company and its directors. At the time of the Quirk and Bear complaint, the Company had stated its intent to schedule a shareholder meeting no later than June 30, 2020, and in fact did hold the shareholder meeting on May 27, 2020. On March 2, 2020, Quirk and Bear filed a notice of dismissal in DeKalb County. Quirk and Bear subsequently filed a new lawsuit in Fulton County Superior Court based on substantially similar allegations and seeking similar relief. On March 4, 2020, the Fulton County court ordered a hearing on the emergency motion for a temporary restraining order against the Company for the following day. At the hearing on March 5, 2020, Quirk and Bear presented their version of the facts through affidavits submitted by both Quirk and Bear, arguing that the affidavits supported the emergency relief they sought. The judge denied the motion and did not enter a temporary restraining order. The court set an evidentiary hearing on Quirk and Bear’s motion for a preliminary injunction for March 27, 2020. Due to the Covid-19 pandemic and multiple requests by Quirk and Bear, the scheduling of the hearing was cancelled. Quirk and Bear did not attempt to reschedule it. On September 2, 2020, the Company moved to dismiss the complaint on the grounds that Quirk and Bear lacked standing and failed to state claims for relief. Facing the Company’s motion to dismiss, on September 23, 2020, Quirk voluntarily dismissed his claims against the Company. Because this was the second dismissal of these claims, that dismissal was with prejudice and constitutes an adjudication of the merits under O.C.G.A. § 9-11-41(a)(3). Bear remained a plaintiff in the case. Due to Bear’s refusal to participate in discovery and repeated violations of the Court’s orders, the Company filed a Motion for Involuntary Dismissal of Plaintiff’s Complaint with Prejudice and Incorporated Memorandum of Law on March 2, 2021. Among the request in the motion, the Company asked the Court to award attorney’s fees and costs against Bear as a result of abusive litigation. Subsequently, the Court held a hearing regarding the Company’s motion on March 25, 2021. At that hearing, the Court ordered Bear to appear for her deposition to be taken remotely on March 31, 2021, and April 1, 2021. The Court warned Bear that her failure to appear at these depositions or to participate fully in them would result in the dismissal of the case with prejudice. Bear did not appear for the March 31, 2021, deposition. As a result, on April 6, 2021, the Court issued an Order Granting Motion for Involuntary Dismissal of Plaintiff’s Complaint with Prejudice and Final Order and Judgment (the “Ruling”) against Bear. Among other findings in the Ruling, the Court found that Bear knowingly and willfully failed to participate in discovery and violated the Court’s orders. Consequently, the Court entered final judgment against Bear and in favor of the Company on all counts. In light of the Court’s ruling, the Company intends to seek reimbursement of its attorneys’ fees and costs against Bear for bringing the action. Legal fees for this matter were $ 0 32,000 43,000 184,000 Vennwest Matter On September 24, 2020, the Company accepted service of a lawsuit filed by Vennwest Global Technologies, Inc. (“Vennwest”), a company owned by shareholder Laurie Venning (“Venning”) from Alberta, Canada. The Vennwest lawsuit contains virtually identical claims against HDC that Quirk and Bear alleged. For this reason, the Company believes Venning, Quirk, Bear and others coordinated their irresponsible and costly attacks against the Company, its directors, and others. As Quirk’s dismissal and the Bear judgment reflects, the Company believes these claims are without merit and serve only to deplete the Company’s resources to the detriment of its shareholders. On November 2, 2020, the Company moved to dismiss the complaint or stay the action pending the conclusion of the Quirk and Bear case, on the grounds that the first-filed derivative case would serve as res judicata to preclude the later-filed case. On November 30, 2020, Vennwest filed its response, and on December 15, 2020, the Company filed its reply. On June 8, 2021, the judge ruled to allow the case to proceed, and the parties are now in discovery phase of the case. The Company will vigorously defend itself against these claims and evaluate all options against the plaintiffs including, but not limited to, pursuing counterclaims. Although the Company believes that it will ultimately be successful in its defense, there can be no assurance that the Company will be successful in its defense. Should Vennwest be successful, the outcome could have a material adverse effect on the Company. Legal fees for this matter were $ 0 20,000 0

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 11 – SUBSEQUENT EVENTS The Company has evaluated subsequent events occurring through the date that the financial statements were available to be issued, for events requiring recording or disclosure in the June 30, 2021, financial statements. Other than disclosed earlier in these financial statements, there were no material events or transactions occurring during this period requiring recognition or disclosure.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Patents	Patents Initial costs paid to purchase patents are capitalized and amortized using the straight-line method over the remaining life of the patent, generally 17 years, beginning on the date the patent is issued. Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the costs capitalized to date in the period of abandonment or earlier if abandonment appears probable. The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the three and six months ended June 30, 2021, and 2020 there was no no
Common Stock Warrants Liability	Common Stock Warrants Liability The Company has, from time to time beginning in 2014, issued convertible preferred stock, preferred stock warrants, common stock, common stock warrants, and fully vested options to purchase shares of common stock in excess of its available shares of underlying stock to be issued. In the event the number of shares or warrants of common stock granted exceeds the number of shares available if the holders exercised all of the previously issued outstanding options and warrants, the Company accounts for this excess as a derivative which is recorded as a common stock warrants liability, which is adjusted to fair value at the end of each reporting period. If and when the Company authorizes sufficient shares of common stock and preferred stock, the common stock warrants liability is reclassified to equity at the fair value of the liability at the date of reclassification. The Company accounts for the See further discussion in Note 6 –Shareholders’ Equity (Deficit) and Note 7– Common Stock Warrants Liability.
Stock-based Compensation	Stock-based Compensation Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period using the straight-line method. Valuation and Amortization Method Expected Term Expected Volatility – Risk-Free Interest Rate
Cash	Cash Cash includes cash deposited with financial institutions. Periodically, we maintain deposits in financial institutions in excess of government-insured limits. We believe we are not exposed to significant credit risk and to date, we have not realized any losses on these deposits.

NET (LOSS) INCOME PER SHARE (Ta

NET (LOSS) INCOME PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Computation of earnings per share	Computation of earnings per share Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net (loss) income, in thousands $ (1,674 ) $ 1,412 $ (2,056 ) $ (105 ) Weighted average shares outstanding – basic 404,348,966 393,553,617 404,197,791 391,113,557 Effect of dilutive securities: Shares issuable on conversion of options and warrants – 34,376,539 – – Shares issuable on conversion of convertible debt – 15,398,551 – – Shares issuable on conversion of Series D convertible preferred stock – 20,991,891 – – Weighted average shares outstanding – diluted 404,348,966 464,320,598 404,197,791 391,113,557 (Loss) Earnings per share: Basic $ (0.004 ) $ 0.004 $ (0.005 ) $ – Diluted $ (0.004 ) $ 0.003 $ (0.005 ) $ – Anti-dilutive shares excluded: Shares issuable on conversion of options and warrants 94,587,577 – 82,597,604 37,732,532 Shares issuable on conversion of convertible debt 16,728,311 – 16,728,311 15,398,551 Shares issuable on conversion of Series D convertible preferred stock 20,991,891 – 20,991,891 20,991,891

STOCK-BASED COMPENSATION AND _2

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	Schedule of stock option activity Shares Weighted-Average Outstanding, December 31, 2020 63,875,000 $ 0.025 Granted 23,000,000 $ 0.065 Exercised – $ – Forfeited – $ – Outstanding and exercisable, June 30, 2021 86,875,000 $ 0.036
Schedule of common stock warrant activity	Schedule of common stock warrant activity Shares Weighted-Average Outstanding, December 31, 2020 115,983,781 $ 0.025 Granted – $ – Exercised (333,333 ) $ (0.03 ) Forfeited – $ – Outstanding, June 30, 2021 115,650,448 $ 0.025

COMMON STOCK WARRANTS LIABILI_2

COMMON STOCK WARRANTS LIABILITY (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Reconciliation of warrant liability	Reconciliation of warrant liability Common Stock Warrants Liability Balance, December 31, 2019 $ 1,898 Change in fair value of common stock warrants liability (992 ) Reclassification of common stock warrants liability to equity (906 ) Balance, June 30, 2020 $ –

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash	$ 485	$ 917	$ 1,662	$ 2,296

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Amortization of patents	$ 0	$ 0	$ 0	$ 0
Impairment of intangible assets	$ 0	$ 0	$ 0	$ 0

NET (LOSS) INCOME PER SHARE (De

NET (LOSS) INCOME PER SHARE (Details - Earnings per Share) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net (loss) income, in thousands	$ (1,674)	$ 1,412	$ (2,056)	$ (105)
Weighted average shares outstanding – basic	404,348,966	393,553,617	404,197,791	391,113,557
Effect of dilutive securities:
Shares issuable on conversion of options and warrants	0	34,376,539	0	0
Shares issuable on conversion of convertible debt	0	15,398,551	0	0
Shares issuable on conversion of Series D convertible preferred stock	0	20,991,891	0	0
Weighted average shares outstanding – diluted	404,348,966	464,320,598	404,197,791	391,113,557
(Loss) Earnings per share:
Basic	$ (0.004)	$ 0.004	$ (0.005)
Diluted	$ (0.004)	$ 0.003	$ (0.005)
Options And Warrants [Member]
(Loss) Earnings per share:
Antidilutive shares excluded	94,587,577	0	82,597,604	37,732,532
Conversion Of Convertible Debt [Member]
(Loss) Earnings per share:
Antidilutive shares excluded	16,728,311	0	16,728,311	15,398,551
Conv Series D Conv Pref Stock [Member]
(Loss) Earnings per share:
Antidilutive shares excluded	20,991,891	0	20,991,891	20,991,891

NET (LOSS) INCOME PER SHARE (_2

NET (LOSS) INCOME PER SHARE (Details Narrative) - Options And Warrants [Member] - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	94,587,577	0	82,597,604	37,732,532
Price Below Average [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	6,108,502	105,869,976	9,951,284	22,843,491

STOCK-BASED COMPENSATION AND _3

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details - Option Activity) - Equity Option [Member]	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning | shares	63,875,000
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 0.025
Number of Options Granted | shares	23,000,000
Weighted Average Exercise Price Granted | $ / shares	$ 0.065
Number of Options Exercised | shares	0
Weighted Average Exercise Price Exercised | $ / shares	$ 0
Number of Options Forfeited | shares	0
Weighted Average Exercise Price Forfeited | $ / shares	$ 0
Number of Options Outstanding, Ending | shares	86,875,000
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 0.036

STOCK-BASED COMPENSATION AND _4

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details - Warrant Activity) - Warrant [Member]	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Beginning | shares	115,983,781
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 0.025
Number of Warrants Granted | shares	0
Weighted Average Exercise Price Granted | $ / shares	$ 0
Number of Warrants Exercised | shares	(333,333)
Weighted Average Exercise Price Exercised | $ / shares	$ (0.03)
Number of Warrants Forfeited | shares	0
Weighted Average Exercise Price Forfeited | $ / shares	$ 0
Number of Warrants Outstanding, Ending | shares	115,650,448
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 0.025

STOCK-BASED COMPENSATION AND _5

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 29, 2021	Jun. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,400,000	$ 268,000	$ 1,400,000		$ 268,000
Mr William Fromholzer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				3,000,000
Ms Colleen Hutchinson [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				3,000,000
Mr Ed Morrison [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				3,000,000
Mr James Murphy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				3,000,000
Dr Hong Zhang [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				5,000,000
Mr George Mc Govern [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				3,000,000
Mr Marty Delmonte [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted				3,000,000
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 0		$ 0
Stock option granted			23,000,000
Options outstanding	86,875,000		86,875,000			63,875,000
Options outstanding exercise price ranges			$0.003 to $0.070
Options And Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value outstanding	$ 7,300,000		$ 7,300,000
Aggregate intrinsic value exercisable	7,300,000		$ 7,300,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercise price				$ 0.065
Stock option expiration date				Jun. 29, 2031
Fair value of stock option granted				$ 0.0595
Expected dividend yield				0.00%
Risk free interest rate				0.37%
Expected life				5 years
Expected volatility				154.00%
Non-cash expense	$ 1,368,500
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of stock option granted			$ 0
Warrants outstanding	115,650,448		115,650,448			115,983,781
Warrants outstanding exercise price ranges			$0.005 to $0.075

PATENTS (Details Narrative)

PATENTS (Details Narrative)	6 Months Ended
	Jun. 30, 2021Integer
Goodwill and Intangible Assets Disclosure [Abstract]
Number of patents	21
Patent expiration dates	2022 to 2033

SHAREHOLDERS_ EQUITY (DEFICIT)

SHAREHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)	Jan. 09, 2021	Feb. 28, 2020	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Class of Stock [Line Items]
Issuance of common stock in settlement of accrued wages, value			$ 213,000		$ 213,000
Chairman Of The Board [Member]
Class of Stock [Line Items]
Issuance of common stock in settlement of accrued wages, value					$ 212,500
Issuance of common stock in settlement of accrued wages, shares					15,398,551
Conversion price			$ 0.0138		$ 0.0138
Warrant [Member]
Class of Stock [Line Items]
Warrants outstanding				115,650,448		115,983,781
Warrant exercise price				$ 0.025		$ 0.025
Warrants Exercise	333,333
Strike Price Per Share	$ 0.03
Warrants outstanding exercise price ranges				$0.005 to $0.075
Equity Option [Member]
Class of Stock [Line Items]
Options outstanding				86,875,000		63,875,000
Options outstanding exercise price ranges				$0.003 to $0.070
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Debt converted, original amount converted		$ 200,000
Interest converted		$ 16,688
Promissory Note Holders [Member]
Class of Stock [Line Items]
Warrants outstanding				41,983,781
Warrant exercise price				$ 0.0103
Warrant expiration date				Jul. 31, 2029
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Accrued dividend				$ 206,637		$ 206,637

COMMON STOCK WARRANTS LIABILI_3

COMMON STOCK WARRANTS LIABILITY (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrant liability, beginning balance	$ 1,898
Change in fair value of common stock warrants liability	(992)
Reclassification of common stock warrants liability to equity	(906)
Warrant liability, ending balance	$ 0

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative)	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Promissory Note Holders [Member] | Series D Preferred Stock [Member]
Debt Conversion [Line Items]
Debt converted, shares issued | shares	20,991,891
Accrued Wages [Member]
Debt Conversion [Line Items]
Wages converted into promissory note | $	$ 212,000
Debt conversion price | $ / shares	$ 0.0138
Debt interest rate	8.00%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Loss Contingencies [Line Items]
Legal fees	$ 116	$ 33	$ 301	$ 185
Intel Lawsuit [Member]
Loss Contingencies [Line Items]
Legal fees	116	0	205	0
Quirk And Bear Matter [Member]
Loss Contingencies [Line Items]
Legal fees	0	32	43	184
Vennwest Matter [Member]
Loss Contingencies [Line Items]
Legal fees	$ 0		$ 20	$ 0
Venning Matter [Member]
Loss Contingencies [Line Items]
Legal fees		$ 0